Therapeutic Asset Ratings
622 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Etx-19477
Breast Cancer
858 Therapeutics, Inc.
P1/2
CC
(40)
Gdc-4198
Breast Cancer
Genentech, Inc.
P1/2
CC
(40)
gm103
Breast Cancer
GeneMedicine Co., Ltd.
P1/2
CC
(40)
her2 fpbmc
Breast Cancer
University of Virginia
P1/2
CC
(40)
Icasp9M28Z T Cell Infusions
Breast Cancer
Memorial Sloan Kettering Cancer Center
P1/2
CC
(40)
INX315
Breast Cancer
Incyclix Bio
P1/2
CC
(40)
LEVAMLODIPINE
Breast Cancer
Tanta University
P1/2
CC
(40)
MANNITOL
Breast Cancer
National Taiwan University Hospital
P1/2
CC
(40)
mdx2001
Breast Cancer
ModeX Therapeutics, An OPKO Health Company
P1/2
CC
(40)
Micardis®
Breast Cancer
Tanta University
P1/2
CC
(40)
Mirdametinib
Breast Cancer
Memorial Sloan Kettering Cancer Center
P1/2
CC
(40)
mt-4561
Breast Cancer
Tanabe Pharma America, Inc.
P1/2
CC
(40)
NEOMYCIN
Breast Cancer
Jewish General Hospital
P1/2
CC
(40)
ngm707
Breast Cancer
NGM Biopharmaceuticals, Inc
P1/2
CC
(40)
Palacaparib
Breast Cancer
AstraZeneca
P1/2
CC
(40)
Pirfenidone
Breast Cancer
Harbin Medical University
P1/2
CC
(40)
POLO-LIKE KINASE 1 INHIBITOR NMS-1286937
Breast Cancer
Antonio Giordano, MD
P1/2
CC
(40)
Pumitamig
Breast Cancer
Bristol-Myers Squibb
P1/2
CC
(40)
Puxitatug Samrotecan
Breast Cancer
AstraZeneca
P1/2
CC
(40)
Rezatapopt
Breast Cancer
PMV Pharmaceuticals, Inc
P1/2
CC
(40)
Shr-A1811 For
Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
P1/2
CC
(40)
SL-28
Breast Cancer
Second Life Therapeutics
P1/2
CC
(40)
Solnerstotug
Breast Cancer
Sensei Biotherapeutics, Inc.
P1/2
CC
(40)
st101
Breast Cancer
Sapience Therapeutics
P1/2
CC
(40)
syh2051
Breast Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.
P1/2
CC
(40)
Showing 401 to 425 of 622 assets
Previous
Page 17 of 25
Next